Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fa

WALTHAM, Mass. , July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-mar

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program

Dyne Therapeutics receives FDA Priority Review for z-rostudirsen in DMD, with a potential U.S. launc

- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Acce

Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven n

Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its prop

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss ma

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-

WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-

- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50

- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -  WALT

DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dy

- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registr

Dyne Therapeutics, Inc. retains a Strong Buy rating, driven by clinical progress in DM1 and DMD prog

DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystroph

WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-s

- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Pr

Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial r

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh

  On Tuesday, 647 companies set new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.

    On Friday, 209 companies set new 52-week lows.